Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT02967939 Completed - Clinical trials for Hepatitis B, Chronic

Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

Start date: March 28, 2017
Phase: Phase 3
Study type: Interventional

A study demonstrates the non-inferiority of DA-2802 when compared with ㅍViread® in chronic hepatitis B patients

NCT ID: NCT02966795 Completed - Clinical trials for Hepatitis C Virus (HCV)

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

ENDURANCE-5 6
Start date: January 25, 2017
Phase: Phase 3
Study type: Interventional

A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated cirrhosis respectively.

NCT ID: NCT02965859 Recruiting - Chronic Hepatitis B Clinical Trials

The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

Start date: December 2012
Phase: Phase 2
Study type: Interventional

The study objective is to evaluate the safety and effectiveness of different doses of Metacavir Enteric-coated Capsules in treatment of chronic hepatitis B,as well as to find an appropriate clinical dosage by comparing the effect of different doses of treatment,in order to provide references of clinical trial of the next phase.

NCT ID: NCT02964910 Completed - Hepatitis E Clinical Trials

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )

Start date: August 2016
Phase: Phase 4
Study type: Interventional

This phase IV clinical study was designed to evaluate the immunogenicity and safety of Hecolin® in the chronic Hepatitis B patients on the clinical stability.

NCT ID: NCT02964091 Completed - Chronic Hepatitis C Clinical Trials

Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

SHARED
Start date: October 2016
Phase: Phase 4
Study type: Interventional

The main purpose of the study is to evaluate the efficacy, safety and tolerability of a medication, ledipasvir/sofosbuvir (LDV/SOF), used to treat individuals with chronic hepatitis C virus (HCV) in Rwandan adults. A sub-cohort of participants will have limited laboratory monitoring to determine the minimum laboratory tests necessary.

NCT ID: NCT02963714 Completed - Hepatitis B Vaccine Clinical Trials

Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients

Start date: December 2014
Phase: Phase 4
Study type: Interventional

Intramuscular injection of 40 μg hepatitis B vaccine in a standard three-dose schedule or a four-dose schedule is recommended for hemodialysis patients. However, seroconversion rates are inadequate and persistence of immunity remains a challenge. This is a randomized, controlled trial. The study will evaluate the immunogenicity, immune persistence, and safety of 20 µg and 60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6 in hemodialysis patients.

NCT ID: NCT02959775 Completed - Clinical trials for Hepatitis B Vaccination

Immunogenicity of Hepatitis B Vaccination Among Drug Users

Start date: August 2014
Phase: Phase 4
Study type: Interventional

Uptake, adherence, and completion of vaccination among drug users were low, and their immune function and immune response to hepatitis B vaccination were also suboptimal, indicating that the current practice of hepatitis B vaccination can't protect drug users from HBV infection. This is a randomized, open-label, blank-controlled trial, conducted among drug users with drug rehabilitation. This study will compare the immunogenicity and safety of three intramuscular 20µg and 60µg recombinant hepatitis B vaccines at months 0, 1, and 6 among drug users

NCT ID: NCT02959684 Recruiting - HIV Clinical Trials

Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France

STRADA
Start date: April 14, 2017
Phase:
Study type: Observational

To evaluate the efficacy of a new screening for infectious diseases: tuberculosis, HIV, HBV and HCV, based on risk factors questionnaires (TB screen for tuberculosis and TROD screen for HIV and hepatitis) amongst a population of legal migrants during their mandatory medical check-up. This study aims for a global improvement of screening and care for migrants.

NCT ID: NCT02957994 Active, not recruiting - Hepatitis B Clinical Trials

TAF Switch Study in Hepatitis B Monoinfection

Start date: December 22, 2016
Phase: Phase 4
Study type: Interventional

To evaluate various markers of renal function and bone density after the switch to Tenofovir alafenamide fumarate (TAF) in chronic hepatitis B patients who are currently treated with Tenofovir disoproxil fumarate (TDF) .

NCT ID: NCT02956850 Completed - Clinical trials for Hepatitis B, Chronic

A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531

Start date: December 12, 2016
Phase: Phase 1
Study type: Interventional

This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic hepatitis B. Part I will be conducted in two portions: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) which will include only healthy volunteers. Part II will commence after completion of the MAD portion of Part I and will include only Chronic Hepatitis B (CHB) participants.